Patient considerations in the management of chronic constipation: Focus on prucalopride

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Chronic constipation is a common condition that significantly impacts health care utilization, productivity, and quality of life. Laxatives are commonly used, although often insufficient in restoring normal bowel function or providing adequate relief. There remains a significant need for the development of novel agents to optimize treatment of this condition. This review provides an overview of the preclinical and clinical trial data, supporting the efficacy and safety of prucalopride, a highly selective 5-HT4 receptor agonist that has been approved by the European Medicine Agency for the treatment of chronic constipation in adults who have failed standard laxative therapy. Unlike older 5-HT4 agonists, prucalopride has not been associated with adverse cardiovascular side effects or QT prolongation owing to its high selectivity and affinity for the 5-HT4 receptor without clinically significant cross-reactivity at the human ether-à-go-go-related gene (hERG) potassium channel or 5-HT receptor subtypes that have previously been implicated in adverse cardiovascular events and arrhythmias. Careful safety assessments have documented the relative safety and tolerability of this agent in various patient groups. Focus has also been placed on demonstrating efficacy with regard to bowel function, symptoms, and patient-reported outcomes such as the Patient Assessment of Constipation-Symptoms and the Patient Assessment of Constipation Quality of Life scores to support the use of prucalopride as a safe and effective therapeutic option for the management of chronic constipation.

Original languageEnglish (US)
Pages (from-to)1373-1384
Number of pages12
JournalPatient Preference and Adherence
Volume10
DOIs
StatePublished - Jul 28 2016

Fingerprint

prucalopride
Constipation
Serotonin 5-HT4 Receptor Agonists
Receptors, Serotonin, 5-HT4
quality of life
Laxatives
management
Safety
Patient Acceptance of Health Care
Quality of Life
productivity
utilization
medicine
Symptom Assessment
health care
Serotonin Receptors
Potassium Channels
Therapeutics
event
Ether

Keywords

  • 5-HT agonist
  • Chronic constipation
  • PAC-QOL
  • Prokinetic
  • Prucalopride
  • Safety

ASJC Scopus subject areas

  • Social Sciences (miscellaneous)
  • Medicine (miscellaneous)
  • Health Policy
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Cite this

Patient considerations in the management of chronic constipation : Focus on prucalopride. / Shin, Andrea.

In: Patient Preference and Adherence, Vol. 10, 28.07.2016, p. 1373-1384.

Research output: Contribution to journalReview article

@article{2a874a6c601d49b5ac02ffee0974452e,
title = "Patient considerations in the management of chronic constipation: Focus on prucalopride",
abstract = "Chronic constipation is a common condition that significantly impacts health care utilization, productivity, and quality of life. Laxatives are commonly used, although often insufficient in restoring normal bowel function or providing adequate relief. There remains a significant need for the development of novel agents to optimize treatment of this condition. This review provides an overview of the preclinical and clinical trial data, supporting the efficacy and safety of prucalopride, a highly selective 5-HT4 receptor agonist that has been approved by the European Medicine Agency for the treatment of chronic constipation in adults who have failed standard laxative therapy. Unlike older 5-HT4 agonists, prucalopride has not been associated with adverse cardiovascular side effects or QT prolongation owing to its high selectivity and affinity for the 5-HT4 receptor without clinically significant cross-reactivity at the human ether-{\`a}-go-go-related gene (hERG) potassium channel or 5-HT receptor subtypes that have previously been implicated in adverse cardiovascular events and arrhythmias. Careful safety assessments have documented the relative safety and tolerability of this agent in various patient groups. Focus has also been placed on demonstrating efficacy with regard to bowel function, symptoms, and patient-reported outcomes such as the Patient Assessment of Constipation-Symptoms and the Patient Assessment of Constipation Quality of Life scores to support the use of prucalopride as a safe and effective therapeutic option for the management of chronic constipation.",
keywords = "5-HT agonist, Chronic constipation, PAC-QOL, Prokinetic, Prucalopride, Safety",
author = "Andrea Shin",
year = "2016",
month = "7",
day = "28",
doi = "10.2147/PPA.S92550",
language = "English (US)",
volume = "10",
pages = "1373--1384",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Patient considerations in the management of chronic constipation

T2 - Focus on prucalopride

AU - Shin, Andrea

PY - 2016/7/28

Y1 - 2016/7/28

N2 - Chronic constipation is a common condition that significantly impacts health care utilization, productivity, and quality of life. Laxatives are commonly used, although often insufficient in restoring normal bowel function or providing adequate relief. There remains a significant need for the development of novel agents to optimize treatment of this condition. This review provides an overview of the preclinical and clinical trial data, supporting the efficacy and safety of prucalopride, a highly selective 5-HT4 receptor agonist that has been approved by the European Medicine Agency for the treatment of chronic constipation in adults who have failed standard laxative therapy. Unlike older 5-HT4 agonists, prucalopride has not been associated with adverse cardiovascular side effects or QT prolongation owing to its high selectivity and affinity for the 5-HT4 receptor without clinically significant cross-reactivity at the human ether-à-go-go-related gene (hERG) potassium channel or 5-HT receptor subtypes that have previously been implicated in adverse cardiovascular events and arrhythmias. Careful safety assessments have documented the relative safety and tolerability of this agent in various patient groups. Focus has also been placed on demonstrating efficacy with regard to bowel function, symptoms, and patient-reported outcomes such as the Patient Assessment of Constipation-Symptoms and the Patient Assessment of Constipation Quality of Life scores to support the use of prucalopride as a safe and effective therapeutic option for the management of chronic constipation.

AB - Chronic constipation is a common condition that significantly impacts health care utilization, productivity, and quality of life. Laxatives are commonly used, although often insufficient in restoring normal bowel function or providing adequate relief. There remains a significant need for the development of novel agents to optimize treatment of this condition. This review provides an overview of the preclinical and clinical trial data, supporting the efficacy and safety of prucalopride, a highly selective 5-HT4 receptor agonist that has been approved by the European Medicine Agency for the treatment of chronic constipation in adults who have failed standard laxative therapy. Unlike older 5-HT4 agonists, prucalopride has not been associated with adverse cardiovascular side effects or QT prolongation owing to its high selectivity and affinity for the 5-HT4 receptor without clinically significant cross-reactivity at the human ether-à-go-go-related gene (hERG) potassium channel or 5-HT receptor subtypes that have previously been implicated in adverse cardiovascular events and arrhythmias. Careful safety assessments have documented the relative safety and tolerability of this agent in various patient groups. Focus has also been placed on demonstrating efficacy with regard to bowel function, symptoms, and patient-reported outcomes such as the Patient Assessment of Constipation-Symptoms and the Patient Assessment of Constipation Quality of Life scores to support the use of prucalopride as a safe and effective therapeutic option for the management of chronic constipation.

KW - 5-HT agonist

KW - Chronic constipation

KW - PAC-QOL

KW - Prokinetic

KW - Prucalopride

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=84984996482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984996482&partnerID=8YFLogxK

U2 - 10.2147/PPA.S92550

DO - 10.2147/PPA.S92550

M3 - Review article

AN - SCOPUS:84984996482

VL - 10

SP - 1373

EP - 1384

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -